Annals of Surgical Oncology

, Volume 26, Issue 2, pp 336–342 | Cite as

Does Lymph Node Status Prior to Neoadjuvant Chemotherapy Influence the Number of Sentinel Nodes Removed?

  • Jennifer L. Baker
  • Shirin Muhsen
  • Emily C. Zabor
  • Michelle Stempel
  • Mary L. GemignaniEmail author
Breast Oncology



Recent prospective trials support the use of sentinel lymph node biopsy (SLNB) in breast cancer patients after neoadjuvant chemotherapy (NAC) with a lower false-negative rate if three or more sentinel lymph nodes (SLNs) are identified. In this study, we investigated whether the pre-NAC axillary lymph node status influences the number of SLNs identified.


Stage I–III breast cancer patients who received NAC and underwent SLNB from May 2014 to April 2016 were identified from an institutional prospective database. Clinical and pathological factors among clinically node-negative (cN−) and clinically node-positive (cN+) patients who converted to cN− post-NAC were compared. Generalized linear mixed models analyzed factors associated with the number of SLNs removed.


Among 343 patients who underwent SLNB during the study period, 335 (98%) had at least one SLN identified, and subsequently comprised the study population. The median number of SLNs identified was 4 (range 1–14), which did not differ according to pre-NAC nodal status (P = 0.15). Overall, 85% of patients had three or more SLNs identified (80% cN− group vs. 89% cN+ group; P = 0.02). On univariable analysis, age < 50 years and presenting with a positive axillary node were significantly associated with identifying three or more SLNs.


Our study confirms that SLNB was successfully performed in 98% of our patients after NAC, with very few failed mapping procedures. In the post-NAC setting, the median number of SLNs identified was four, and the status of the axilla prior to NAC did not negatively affect the number of SLNs identified.



The preparation of this manuscript was funded in part by NIH/NCI Cancer Center Support Grant No. P30 CA008748 to Memorial Sloan Kettering Cancer Center.


  1. 1.
    Barrio AV, Mamtani A, Edelweiss M, et al. How often is treatment effect identified in axillary nodes with a pathologic complete response after neoadjuvant chemotherapy? Ann Surg Oncol 2016; 23(11):3475–80.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15(7):2483–93.CrossRefPubMedGoogle Scholar
  3. 3.
    Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg 2014; 260(4):608–14; (discussion 14–6).CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Classe JM, Bordes V, Campion L, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol 2009; 27(5):726–32.CrossRefPubMedGoogle Scholar
  5. 5.
    Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2005; 23(12):2694–702.CrossRefPubMedGoogle Scholar
  6. 6.
    Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013; 310(14):1455–61.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013; 14(7):609–18.CrossRefPubMedGoogle Scholar
  8. 8.
    Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 2015; 33(3):258–64.CrossRefPubMedGoogle Scholar
  9. 9.
    National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, Breast Cancer. Version. 1.2018.Google Scholar
  10. 10.
    Alvarado R, Yi M, Le-Petross H, et al. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol 2012; 19(10):3177–84.CrossRefPubMedGoogle Scholar
  11. 11.
    Sharkey FE, Addington SL, Fowler LJ, Page CP, Cruz AB. Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma. Mod Pathol 1996; 9(9):893–900.PubMedGoogle Scholar
  12. 12.
    Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002; 95(4):681–95.CrossRefPubMedGoogle Scholar
  13. 13.
    Donker M, Straver ME, Wesseling J, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg 2015; 261(2):378–82.CrossRefPubMedGoogle Scholar
  14. 14.
    Ahmed M, Douek M. Targeted axillary dissection after neoadjuvant therapy in breast cancer. Br J Surg 2018; 105(4):313–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 2016; 34(10):1072–8.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Port ER, Patil S, Stempel M, Morrow M, Cody HS 3rd. Number of lymph nodes removed in sentinel lymph node-negative breast cancer patients is significantly related to patient age and tumor size: a new source of bias in morbidity assessment? Cancer 2010; 116(8):1987–91.CrossRefPubMedGoogle Scholar
  17. 17.
    Subhedar P, Stempel M, Eaton A, Morrow M, Gemignani ML. Do the ACOSOG Z0011 criteria affect the number of sentinel lymph nodes removed? Ann Surg Oncol 2015; 22 Suppl 3:S470–5.CrossRefPubMedGoogle Scholar
  18. 18.
    McCarter MD, Yeung H, Fey J, Borgen PI, Cody HS 3rd. The breast cancer patient with multiple sentinel nodes: when to stop? J Am Coll Surg 2001; 192(6):692–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007; 8(10):881–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Boughey JC, Suman VJ, Mittendorf EA, et al. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg 2015; 261(3):547–52.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) Who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg 2016; 263(4):802–7.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Nguyen TT, Hieken TJ, Glazebrook KN, Boughey JC. Localizing the clipped node in patients with node-positive breast cancer treated with neoadjuvant chemotherapy: early learning experience and challenges. Ann Surg Oncol 2017; 24(10):3011–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010; 11(10):927–33.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Galimberti V, Ribeiro Fontana SK, Maisonneuve P, et al. Sentinel node biopsy after neoadjuvant treatment in breast cancer: five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol 2016; 42(3):361–8.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Jennifer L. Baker
    • 1
  • Shirin Muhsen
    • 1
  • Emily C. Zabor
    • 2
  • Michelle Stempel
    • 1
  • Mary L. Gemignani
    • 1
    Email author
  1. 1.Breast Service, Department of SurgeryMemorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.Biostatistics Service, Department of Epidemiology and BiostatisticsMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations